Trial Profile
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Amantadine (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Acronyms EASE LID 3
- Sponsors Adamas Pharmaceuticals
- 26 Apr 2022 Results of pooled analysis from EASE LID, EASE LID 2 and EASE LID 3; valuating potential utility of Amantadine for persons with parkinson disease under consideration for device aided therapy, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 16 Sep 2021 According to an Adamas Pharmaceuticals media release, pooled data from GOCOVRI pivotal trials to evaluate efficacy of GOCOVRI as a first/early add-on treatment to levodopa for Parkinson's disease (PD) motor complications (OFF or dyskinesia) will be presented at the International Parkinson and Movement Disorder Society (MDS) 2021 .
- 10 Jun 2021 Data from a post-hoc data analysis from two Phase 3 trials (EASE LID and EASE LID 3) were present in an Adamas Pharmaceuticals Media Release